Shots:

• Mithra to get up front- sales milestones- royalties and recurring revenues based on Minimal Annual Quantities (MAQ) and will manufacture Estelle at its Contract Development and Manufacturing Organization facility in Belgium. Alvogen to get exclusive commercialization rights for Mithra’s Estelle in Hong Kong and Taiwan
• The agreement follows its previous licensing deals for Estelle in the US- EU- Russia- Canada- Brazil- Japan- South Korea- Middle East and South Africa with the focus of adding it to Alvogen’s women healthcare portfolio and develop footprints in Asia  
• Estelle is a combined oral contraceptive (COC) of Estetrol (E4)15 mg & drospirenone (DRSP) 3 mg and has shown positive results including good bleeding profile- cycle control- and tolerability in P-III trial enrolling 3-725 women

Click here to read full press release/ article | Ref: Mithra | Image: PharmaWorld